Title: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Journal: Drugs 20170701
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
Journal: Expert opinion on investigational drugs 20140501
Title: MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
Journal: Antimicrobial agents and chemotherapy 20120801
Title: Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.
Journal: ACS medicinal chemistry letters 20120412
Title: Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7.
Title: Harper S, et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med Chem Lett. 2012 Mar 2;3(4):332-6.
Title: Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
